[536 Pages Report] The global coronavirus immunoassay market reached US$ 3.7 Billion in 2021. With sales growing at a 5.5% CAGR over the assessment period, the market size is projected to surpass US$ 6.9 Billion by 2032. Immunoassay kits & reagents are leading the market with a share of about 64.0% in the year 2021.
| Data Points | Market Insights |
|---|---|
| Coronavirus Immunoassay Market Base Year Value (2021) | US$ 3.7 Billion |
| Projected Market Valuation (2032) | US$ 6.9 Billion |
| Value-based CAGR (2022 to 2032) | 5.5% |
| Market Share of Top 5 Countries | 56.7% |
The global economy has been significantly impacted as a result of business closures and severe travel restrictions caused by the COVID-19 epidemic. The widespread availability of precise and quick testing methodologies is critical for resolving the intricate dynamics of SARS-CoV-2 infection and immunity. Laboratories, universities, and businesses across the globe have been working actively to develop and manufacture vital test kits.
COVID-19 tests that are currently commercially accessible are divided into two groups. The first group includes molecular assays that use polymerase chain reaction (PCR) or nucleic acid hybridization-based techniques to identify SARS-CoV-2 viral RNA. The second group of assays includes serological and immunological tests that primarily rely on detecting antibodies produced by individuals because of virus exposure or on detecting antigenic proteins in infected individuals.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for coronavirus immunoassays was approximately 13.2% of the US$ 28.1 Bn worth global immunoassay market in 2021.
Along with developments in diagnostic testing, researchers are aiming to manufacture different therapies that could be used to treat COVID-19 patients. The diagnosis procedures may be effective in the suppression of COVID-19, allowing for the quick implementation of preventative measures such as identifying and isolating infected individuals and identifying those who have been directly contacted by affected patients.
Biosensors can detect pathogens in a variety of contexts with excellent sensitivity and selectivity without the need for sample preparation. Furthermore, biosensor-based technologies are rapidly emerging as complementary platforms to PCR and ELISA for SARS-CoV-2 identification and quantitative detection.
Moreover, electrochemical biosensors are effective diagnostic instruments that have enabled pathogen detection in a variety of biological specimens without the need for sample preparation, as well as pathogen detection on surfaces and detection via wireless actuation.
The ability to make life-saving decisions on therapeutic measures and the isolation of COVID-19 infected individuals at the earliest possible stage is enhanced by rapid testing, which eventually inhibits the spread of infection.
Owing to the aforementioned factors, the global coronavirus immunoassay market is expected to grow at a CAGR of 5.5% during the forecast period.
To control the severity of the COVID-19 pandemic, the WHO has urged countries around the world to ensure competent surveillance and identification of infected individuals. In such conditions, cutting-edge technologies such as the Internet of Medical Things (IoMT), UVs, GPS, robots, Bluetooth, and drones, can play a critical role in mitigating the impact of the COVID-19 outbreak.
IoT is a promising technology that consists of interconnected computing devices communicating information over a network without the need for human intervention. IoMT has recently attracted a lot of interest from the healthcare community. It is a collection of medical devices and software applications that are linked to healthcare information technology systems.
After the discovery of a vaccine or therapies, the most important issue in the current situation of the COVID-19 crisis is an efficient manner of reaching patients. The Internet of Things (IoT) is the best way to accomplish this.
Drones, robotic systems, and audio-visual technology can help reach contagious COVID-19 patients while requiring minimal human interaction. Wearables that employ Bluetooth and GPS technology are other effective approaches to track an individual's health and stress levels on a daily basis.
Overall, these technologies have the potential to play a significant role in the new tele-medicine framework, whether for disease prevention or identification and surveillance of the symptomatic, asymptomatic COVID-19 positives, masses, and paramedical staff, thus providing impetus to the growth in the market.
Principal Consultant
Antibody tests are a critical response to virus transmission and provide timely treatment for patients, but global supply constraints and high demand for PCR primers and positive controls have diagnostic companies scurrying to create them.
The inability of many countries and businesses to respond to the COVID-19 pandemic is due to their supply chain-the transport of goods such as masks, ventilators, consumables, and even services (e.g., visiting clinics).
Many countries are also concerned about the lack of personal protective equipment (PPE), which is necessary for frontline healthcare workers to tackle the disease.
In Italy, a lack of personal protective equipment is implicated in increasing rates of infection and death. Many researchers believe the U.S. requires far more respirators and surgical masks than are currently available. The supply chain's susceptibility can be associated with the negative effects of the shortages. These factors act as some of the key limitations in the global coronavirus immunoassay market.
“Increasing Demand for Vital Test Kits in the U.S. Will Boost Sales of Coronavirus Immunoassays”
The U.S. dominated the North America coronavirus immunoassay market, holding around 95.7% of the total market share in 2021.
Ongoing efforts within the country to communicate and facilitate the development of novel diagnostic assays and the worldwide delivery of test kits is expected to fuel sales in the market.
Several organisations are supporting these efforts by requesting assay developers to submit their test products for independent evaluation or by investing in collaborations to promote more accurate and faster diagnostic solutions.
As similar initiatives and knowledge sharing are attainable, including collaborative technological developments, demand for coronavirus immunoassays in the U.S. will increase at a considerable pace over the forecast period.
“Rising Adoption of Molecular Assays in Germany Will Fuel Growth”
Sales in the Germany market are forecast to increase at a 5.5% CAGR over the forecast period. The Health Security Committee (HSC) agreed on Recommendations for a common EU testing methodology for COVID-19 on September 17, 2020, laying out several activities that nations should consider when upgrading or adjusting their testing procedures.
Member States' first experiences with rapid antigen tests, as well as their discussions about the settings and conditions in which these tests should be performed, were incorporated in the Recommendations.
Since then, the HSC has been debating the use and application of rapid antigen testing in-depth, compiling a plethora of (technical) knowledge on the many types of tests used in Europe and the conditions under which they are employed. As a result of the increased prevalence of infection within the country, Germany will exhibit high demand for coronavirus immunoassays.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
“Sales of Kits and Reagents Will Continue Gaining Traction”
Based on product type, sales of immunoassay kits & reagents are expected to increase at a CAGR of 5.4% by the end of the forecast period, holding about 68.3% of the global market in 2032.
Owing to rapid detection of infectious pathogens, as well as the accuracy associated with the prompt detection, sales are expected to increase in this segment. Moreover, greater accessibility of these products across developed, as well as emerging economies have provided more opportunities for the expansion of the coronavirus immunoassay market.
“Demand for LFA Immunoassays Will Increase Over the Forecast Period”
In terms of assay type, the LFA segment held 39.0% of the total market share in 2021, and is expected to account for 45.0% in 2032. LFA is a one-step, cost-effective and rapid assay. They are critical in instances of point-of-care, and have a long shelf life, with no need for refrigeration. These factors allow a higher adoption of these assays, thus propelling the sales.
“Nasopharynx Segment to Remain the Most Lucrative”
By specimen type, specimen collection through the nasopharynx held a dominant share value of around 38.9% in 2021. For the diagnosis of COVID-19 in adults and children, nasopharyngeal swabs are used to collect samples from the surface of the respiratory mucosa. Patients with suspected respiratory infections caused by other viruses or bacteria are frequently evaluated using this method.
“Applications of Coronavirus Immunoassays for Clinical Diagnosis Will Gain Momentum”
Total demand in the clinical diagnosis segment held around 66.4% of the total market share in 2021. With evolving dynamics in disease epidemiology, rising number of infectious cases, growing global burden of disease, and increasing efforts to enhance healthcare infrastructure, clinical diagnosis of disease will be necessary in assessing the impact of disease and its causative factors.
“Adoption of Coronavirus Immunoassays in the Healthcare Sector Will Bolster”
The healthcare sector held around 94.4% of the total market share in 2021 and the trend is expected to continue over the assessment period. Collaborative efforts by manufacturers as well as policy makers in the design and development of rapid diagnostic tests, along with the available facilities to promote accessibility of these products globally, the healthcare industry owns a dominant stance in the coronavirus immunoassay market.
To meet unmet patient demand, key companies are pursuing strategic initiatives in the field of immunoassays, spanning acquisitions and mergers, development of new products, and geographic coverage. Instances of key developmental strategies by the industry players in the coronavirus immunoassay market are given below:
| Attributes | Details |
|---|---|
| Base Yeas Market Size (2022) | US$ 3.7 Billion |
| Projected Market Valuation (2032) | US$ 6.9 Billion |
| Value-based CAGR (2032) | 5.5% |
| Forecast Period | 2012 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, The UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, and South Africa |
| Key Market Segments Covered | Product, Assay, Purpose, Specimen, Application, End User, and Region |
| Key Companies Profiled |
|
The global coronavirus immunoassay market is worth US$ 3.7 Bn in 2021, and is set to expand ~1.9X over the next ten years.
The coronavirus immunoassay market is expected to reach US$ 6.9 Bn by the end of 2032, with sales revenue expected to register 5.5% CAGR.
Demand in industrial applications driving immunoassay market, and strategic acquisitions and partnerships are some of the key trends in this market.
The U.S., China, Japan, Germany, and the U.K. are expected to drive demand for the coronavirus immunoassay industry.
North America is one of the key markets for coronavirus immunoassay, with the U.S. accounting for about 95.7% of the North American coronavirus immunoassay market in the year 2021.
Demand for coronavirus immunoassay in Europe is expected to register a growth of 4.5% over the next ten years.
The U.S., China, and Japan are the key producers in the coronavirus immunoassay market space.
Surmodics, Inc., MESO SCALE DIAGNOSTICS, LLC., Abbott (Core Laboratory), Siemens-healthineers (Siemens Medical Solutions USA, Inc), PerkinElmer Inc., BD Biosciences, ThermoFisher Scientific Inc., Zoetis Inc., Promega Corporation, F. Hoffmann- La Roche Ltd., bioMérieux SA, Elabscience Biotechnology Inc., Innovative Research, Inc., QIAGEN N.V., Merck KgaA, Bio-Rad Laboratories, Inc., Creative Diagnostics, Cell Signaling Technology, Inc., NEW HORIZONS DIAGNOSTIC CORPORATION, DiaSorin S.p.A., H.U. G
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions & Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Disease Epidemiology
4.2. Key Strategies, by Market Players
4.3. Technological Advancements
4.4. New Product launches & Approvals
4.5. Regulatory landscape
4.6. Reimbursement Scenario
4.7. Value Chain Analysis
4.8. Product Adoption Analysis
4.9. PESTLE Analysis
4.10. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Spending Outlook
5.1.3. Global Healthcare Expenditure Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. New/Improved Product Launches
5.2.2. Growing prevalence of Chronic and infectious disease
5.2.3. Growing research and development funding
5.2.4. Demand for clinical diagnosis
5.2.5. Growing adoption of immunoassay based point-of-care diagnostics
5.2.6. Increase in research institutes and its activities
5.2.7. Global manufacturers focusing on Emerging Markets
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 Impact Analysis
6.1.1. Revenue by Product
6.1.2. Revenue by Assay
6.1.3. Revenue by Purpose
6.1.4. Revenue by Specimen
6.1.5. Revenue by Application
6.1.6. Revenue by End-User
6.1.7. Revenue by Region
6.2. 2021 Market Scenario
7. Global Coronavirus Immunoassay Market Demand (in Value or Size in US$ Bn) Analysis 2012-2021 and Forecast, 2022–2032
7.1. Historical Market Value (US$ Bn) Analysis, 2012-2021
7.2. Current and Future Market Value (US$ Bn) Projections, 2022–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Coronavirus Immunoassay Market Analysis 2012-2021 and Forecast 2022–2032, by Product
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis By Product, 2012-2021
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product, 2022–2032
8.3.1. Immunoassay Kits & Reagents
8.3.1.1. Kits
8.3.1.2. Primary Antibodies
8.3.1.3. Secondary antibodies
8.3.1.4. Immunoassay Substrates
8.3.1.5. Immunoassay Buffers
8.3.2. Analyzers & Instrument
8.3.3. Consumables
8.3.4. Software
8.4. Market Attractiveness Analysis By Product
9. Global Coronavirus Immunoassay Market Analysis 2012-2021 and Forecast 2022–2032, by Assay
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis By Assay, 2012-2021
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Assay, 2022–2032
9.3.1. Enzyme immunoassay (EIA) or Enzyme linked immunosorbent assay ( ELISA)
9.3.2. Fluroimmunoassay (FIA)
9.3.3. Chemiluminiscent Immunoassay (CLIA)
9.3.4. Lateral Flow Assay (LFA)
9.3.5. Others
9.4. Market Attractiveness Analysis By Assay
10. Global Coronavirus Immunoassay Market Analysis 2012-2021 and Forecast 2022–2032, by Purpose
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Analysis By Purpose, 2012-2021
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Purpose, 2022–2032
10.3.1. Research use only
10.3.2. Clinical use
10.4. Market Attractiveness Analysis By Purpose
11. Global Coronavirus Immunoassay Market Analysis 2012-2021 and Forecast 2022–2032, by Specimen
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Bn) Analysis By Specimen, 2012-2021
11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Specimen, 2022–2032
11.3.1. Blood
11.3.2. Saliva
11.3.3. Nasopharynx
11.3.4. Cell culture samples
11.4. Market Attractiveness Analysis By Specimen
12. Global Coronavirus Immunoassay Market Analysis 2012-2021 and Forecast 2022–2032, by Application
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Bn) Analysis By Application, 2012-2021
12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Application, 2022–2032
12.3.1. Clinical diagnostics
12.3.2. Drug discovery
12.3.3. Screening of diseases and disorders
12.4. Market Attractiveness Analysis By Application
13. Global Coronavirus Immunoassay Market Analysis 2012-2021 and Forecast 2022–2032, by End User
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Bn) Analysis By End User, 2012-2021
13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By End User, 2022–2032
13.3.1. Healthcare Industry
13.3.1.1. Human Use
13.3.1.2. Veterinary
13.4. Market Attractiveness Analysis By End User
14. Global Coronavirus Immunoassay Market Analysis 2012-2021 and Forecast 2022–2032, by Region
14.1. Introduction
14.2. Historical Market Size (US$ Bn) Analysis, By Region, 2012-2021
14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2022–2032
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. East Asia
14.3.5. South Asia
14.3.6. Oceania
14.3.7. Middle East and Africa (MEA)
14.4. Market Attractiveness Analysis By Region
15. North America Coronavirus Immunoassay Market Analysis 2012-2021 and Forecast 2022–2032
15.1. Introduction
15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2012-2021
15.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032
15.3.1. By Country
15.3.1.1. U.S.
15.3.1.2. Canada
15.3.2. By Product
15.3.3. By Assay
15.3.4. By Purpose
15.3.5. By Specimen
15.3.6. By Application
15.3.7. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Assay
15.4.4. By Purpose
15.4.5. By Specimen
15.4.6. By Application
15.4.7. By End User
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Country Level Analysis & Forecast
15.7.1. U.S. Coronavirus Immunoassay Market
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Product
15.7.1.2.2. By Assay
15.7.1.2.3. By Purpose
15.7.1.2.4. By Specimen
15.7.1.2.5. By Application
15.7.1.2.6. By End User
15.7.2. Canada Coronavirus Immunoassay Market
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Product
15.7.2.2.2. By Assay
15.7.2.2.3. By Purpose
15.7.2.2.4. By Specimen
15.7.2.2.5. By Application
15.7.2.2.6. By End User
16. Latin America Coronavirus Immunoassay Market Analysis 2012-2021 and Forecast 2022–2032
16.1. Introduction
16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2012-2021
16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032
16.3.1. By Country
16.3.1.1. Brazil
16.3.1.2. Mexico
16.3.1.3. Argentina
16.3.1.4. Rest of Latin America
16.3.2. By Product
16.3.3. By Assay
16.3.4. By Purpose
16.3.5. By Specimen
16.3.6. By Application
16.3.7. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Assay
16.4.4. By Purpose
16.4.5. By Specimen
16.4.6. By Application
16.4.7. By End User
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Country Level Analysis & Forecast
16.7.1. Brazil Coronavirus Immunoassay Market
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Product
16.7.1.2.2. By Assay
16.7.1.2.3. By Purpose
16.7.1.2.4. By Specimen
16.7.1.2.5. By Application
16.7.1.2.6. By End User
16.7.2. Argentina Coronavirus Immunoassay Market
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Product
16.7.2.2.2. By Assay
16.7.2.2.3. By Purpose
16.7.2.2.4. By Specimen
16.7.2.2.5. By Application
16.7.2.2.6. By End User
16.7.3. Mexico Coronavirus Immunoassay Market
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Product
16.7.3.2.2. By Assay
16.7.3.2.3. By Purpose
16.7.3.2.4. By Specimen
16.7.3.2.5. By Application
16.7.3.2.6. By End User
17. Europe Coronavirus Immunoassay Market Analysis 2012-2021 and Forecast 2022–2032
17.1. Introduction
17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2012-2021
17.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032
17.3.1. By Country
17.3.1.1. U.K.
17.3.1.2. Germany
17.3.1.3. Italy
17.3.1.4. France
17.3.1.5. Spain
17.3.1.6. Russia
17.3.1.7. Nordic Countries
17.3.1.8. BENELUX
17.3.1.9. Rest of Europe
17.3.2. By Product
17.3.3. By Assay
17.3.4. By Purpose
17.3.5. By Specimen
17.3.6. By Application
17.3.7. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Assay
17.4.4. By Purpose
17.4.5. By Specimen
17.4.6. By Application
17.4.7. By End User
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Country Level Analysis & Forecast
17.7.1. U.K. Coronavirus Immunoassay Market
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Product
17.7.1.2.2. By Assay
17.7.1.2.3. By Purpose
17.7.1.2.4. By Specimen
17.7.1.2.5. By Application
17.7.1.2.6. By End User
17.7.2. Germany Coronavirus Immunoassay Market
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Product
17.7.2.2.2. By Assay
17.7.2.2.3. By Purpose
17.7.2.2.4. By Specimen
17.7.2.2.5. By Application
17.7.2.2.6. By End User
17.7.3. Italy Coronavirus Immunoassay Market
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Product
17.7.3.2.2. By Assay
17.7.3.2.3. By Purpose
17.7.3.2.4. By Specimen
17.7.3.2.5. By Application
17.7.3.2.6. By End User
17.7.4. France Coronavirus Immunoassay Market
17.7.4.1. Introduction
17.7.4.2. Market Analysis and Forecast by Market Taxonomy
17.7.4.2.1. By Product
17.7.4.2.2. By Assay
17.7.4.2.3. By Purpose
17.7.4.2.4. By Specimen
17.7.4.2.5. By Application
17.7.4.2.6. By End User
17.7.5. Spain Coronavirus Immunoassay Market
17.7.5.1. Introduction
17.7.5.2. Market Analysis and Forecast by Market Taxonomy
17.7.5.2.1. By Product
17.7.5.2.2. By Assay
17.7.5.2.3. By Purpose
17.7.5.2.4. By Specimen
17.7.5.2.5. By Application
17.7.5.2.6. By End User
17.7.6. Russia Coronavirus Immunoassay Market
17.7.6.1. Introduction
17.7.6.2. Market Analysis and Forecast by Market Taxonomy
17.7.6.2.1. By Product
17.7.6.2.2. By Assay
17.7.6.2.3. By Purpose
17.7.6.2.4. By Specimen
17.7.6.2.5. By Application
17.7.6.2.6. By End User
17.7.7. Nordic Countries Coronavirus Immunoassay Market
17.7.7.1. Introduction
17.7.7.2. Market Analysis and Forecast by Market Taxonomy
17.7.7.2.1. By Product
17.7.7.2.2. By Assay
17.7.7.2.3. By Purpose
17.7.7.2.4. By Specimen
17.7.7.2.5. By Application
17.7.7.2.6. By End User
17.7.8. BENELUX Coronavirus Immunoassay Market
17.7.8.1. Introduction
17.7.8.2. Market Analysis and Forecast by Market Taxonomy
17.7.8.2.1. By Product
17.7.8.2.2. By Assay
17.7.8.2.3. By Purpose
17.7.8.2.4. By Specimen
17.7.8.2.5. By Application
17.7.8.2.6. By End User
18. South Asia Coronavirus Immunoassay Market Analysis 2012-2021 and Forecast 2022–2032
18.1. Introduction
18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2012-2021
18.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032
18.3.1. By Country
18.3.1.1. India
18.3.1.2. Thailand
18.3.1.3. Indonesia
18.3.1.4. Malaysia
18.3.1.5. Philippines
18.3.1.6. Vietnam
18.3.1.7. Rest of South Asia
18.3.2. By Product
18.3.3. By Assay
18.3.4. By Purpose
18.3.5. By Specimen
18.3.6. By Application
18.3.7. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By Assay
18.4.4. By Purpose
18.4.5. By Specimen
18.4.6. By Application
18.4.7. By End User
18.5. Market Trends
18.6. Drivers and Restraints - Impact Analysis
18.7. Country Level Analysis & Forecast
18.7.1. India Coronavirus Immunoassay Market
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By Product
18.7.1.2.2. By Assay
18.7.1.2.3. By Purpose
18.7.1.2.4. By Specimen
18.7.1.2.5. By Application
18.7.1.2.6. By End User
18.7.2. Thailand Coronavirus Immunoassay Market
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By Product
18.7.2.2.2. By Assay
18.7.2.2.3. By Purpose
18.7.2.2.4. By Specimen
18.7.2.2.5. By Application
18.7.2.2.6. By End User
18.7.3. Indonesia Coronavirus Immunoassay Market
18.7.3.1. Introduction
18.7.3.2. Market Analysis and Forecast by Market Taxonomy
18.7.3.2.1. By Product
18.7.3.2.2. By Assay
18.7.3.2.3. By Purpose
18.7.3.2.4. By Specimen
18.7.3.2.5. By Application
18.7.3.2.6. By End User
18.7.4. Malaysia Coronavirus Immunoassay Market
18.7.4.1. Introduction
18.7.4.2. Market Analysis and Forecast by Market Taxonomy
18.7.4.2.1. By Product
18.7.4.2.2. By Assay
18.7.4.2.3. By Purpose
18.7.4.2.4. By Specimen
18.7.4.2.5. By Application
18.7.4.2.6. By End User
18.7.5. Philippines Coronavirus Immunoassay Market
18.7.5.1. Introduction
18.7.5.2. Market Analysis and Forecast by Market Taxonomy
18.7.5.2.1. By Product
18.7.5.2.2. By Assay
18.7.5.2.3. By Purpose
18.7.5.2.4. By Specimen
18.7.5.2.5. By Application
18.7.5.2.6. By End User
18.7.6. Vietnam Coronavirus Immunoassay Market
18.7.6.1. Introduction
18.7.6.2. Market Analysis and Forecast by Market Taxonomy
18.7.6.2.1. By Product
18.7.6.2.2. By Assay
18.7.6.2.3. By Purpose
18.7.6.2.4. By Specimen
18.7.6.2.5. By Application
18.7.6.2.6. By End User
19. East Asia Coronavirus Immunoassay Market Analysis 2012-2021 and Forecast 2022–2032
19.1. Introduction
19.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2012-2021
19.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032
19.3.1. By Country
19.3.1.1. China
19.3.1.2. Japan
19.3.1.3. South Korea
19.3.2. By Product
19.3.3. By Assay
19.3.4. By Purpose
19.3.5. By Specimen
19.3.6. By Application
19.3.7. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Product
19.4.3. By Assay
19.4.4. By Purpose
19.4.5. By Specimen
19.4.6. By Application
19.4.7. By End User
19.5. Market Trends
19.6. Drivers and Restraints - Impact Analysis
19.7. Country Level Analysis & Forecast
19.7.1. China Coronavirus Immunoassay Market
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast by Market Taxonomy
19.7.1.2.1. By Product
19.7.1.2.2. By Assay
19.7.1.2.3. By Purpose
19.7.1.2.4. By Specimen
19.7.1.2.5. By Application
19.7.1.2.6. By End User
19.7.2. Japan Coronavirus Immunoassay Market
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast by Market Taxonomy
19.7.2.2.1. By Product
19.7.2.2.2. By Assay
19.7.2.2.3. By Purpose
19.7.2.2.4. By Specimen
19.7.2.2.5. By Application
19.7.2.2.6. By End User
19.7.3. South Korea Coronavirus Immunoassay Market
19.7.3.1. Introduction
19.7.3.2. Market Analysis and Forecast by Market Taxonomy
19.7.3.2.1. By Product
19.7.3.2.2. By Assay
19.7.3.2.3. By Purpose
19.7.3.2.4. By Specimen
19.7.3.2.5. By Application
19.7.3.2.6. By End User
20. Oceania Coronavirus Immunoassay Market Analysis 2012-2021 and Forecast 2022–2032
20.1. Introduction
20.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2012-2021
20.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032
20.3.1. By Country
20.3.1.1. Australia
20.3.1.2. New Zealand
20.3.2. By Product
20.3.3. By Assay
20.3.4. By Purpose
20.3.5. By Specimen
20.3.6. By Application
20.3.7. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Product
20.4.3. By Assay
20.4.4. By Purpose
20.4.5. By Specimen
20.4.6. By Application
20.4.7. By End User
20.5. Market Trends
20.6. Drivers and Restraints - Impact Analysis
20.7. Country Level Analysis & Forecast
20.7.1. Australia Coronavirus Immunoassay Market
20.7.1.1. Introduction
20.7.1.2. Market Analysis and Forecast by Market Taxonomy
20.7.1.2.1. By Product
20.7.1.2.2. By Assay
20.7.1.2.3. By Purpose
20.7.1.2.4. By Specimen
20.7.1.2.5. By Application
20.7.1.2.6. By End User
20.7.2. New Zealand Coronavirus Immunoassay Market
20.7.2.1. Introduction
20.7.2.2. Market Analysis and Forecast by Market Taxonomy
20.7.2.2.1. By Product
20.7.2.2.2. By Assay
20.7.2.2.3. By Purpose
20.7.2.2.4. By Specimen
20.7.2.2.5. By Application
20.7.2.2.6. By End User
21. Middle East and Africa (MEA) Coronavirus Immunoassay Market Analysis 2012-2021 and Forecast 2022–2032
21.1. Introduction
21.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2012-2021
21.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032
21.3.1. By Country
21.3.1.1. Turkey
21.3.1.2. Egypt
21.3.1.3. GCC Countries
21.3.1.4. North Africa
21.3.1.5. South Africa
21.3.1.6. Rest of Middle East and Africa
21.3.2. By Product
21.3.3. By Assay
21.3.4. By Purpose
21.3.5. By Specimen
21.3.6. By Application
21.3.7. By End User
21.4. Market Attractiveness Analysis
21.4.1. By Country
21.4.2. By Product
21.4.3. By Assay
21.4.4. By Purpose
21.4.5. By Specimen
21.4.6. By Application
21.4.7. By End User
21.5. Market Trends
21.6. Drivers and Restraints - Impact Analysis
21.7. Country Level Analysis & Forecast
21.7.1. Turkey Coronavirus Immunoassay Market
21.7.1.1. Introduction
21.7.1.2. Market Analysis and Forecast by Market Taxonomy
21.7.1.2.1. By Product
21.7.1.2.2. By Assay
21.7.1.2.3. By Purpose
21.7.1.2.4. By Specimen
21.7.1.2.5. By Application
21.7.1.2.6. By End User
21.7.2. Egypt Coronavirus Immunoassay Market
21.7.2.1. Introduction
21.7.2.2. Market Analysis and Forecast by Market Taxonomy
21.7.2.2.1. By Product
21.7.2.2.2. By Assay
21.7.2.2.3. By Purpose
21.7.2.2.4. By Specimen
21.7.2.2.5. By Application
21.7.2.2.6. By End User
21.7.3. GCC Countries Coronavirus Immunoassay Market
21.7.3.1. Introduction
21.7.3.2. Market Analysis and Forecast by Market Taxonomy
21.7.3.2.1. By Product
21.7.3.2.2. By Assay
21.7.3.2.3. By Purpose
21.7.3.2.4. By Specimen
21.7.3.2.5. By Application
21.7.3.2.6. By End User
21.7.4. North Africa Coronavirus Immunoassay Market
21.7.4.1. Introduction
21.7.4.2. Market Analysis and Forecast by Market Taxonomy
21.7.4.2.1. By Product
21.7.4.2.2. By Assay
21.7.4.2.3. By Purpose
21.7.4.2.4. By Specimen
21.7.4.2.5. By Application
21.7.4.2.6. By End User
21.7.5. South Africa Coronavirus Immunoassay Market
21.7.5.1. Introduction
21.7.5.2. Market Analysis and Forecast by Market Taxonomy
21.7.5.2.1. By Product
21.7.5.2.2. By Assay
21.7.5.2.3. By Purpose
21.7.5.2.4. By Specimen
21.7.5.2.5. By Application
21.7.5.2.6. By End User
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Share Analysis of Top Players
22.3. Market Presence Analysis
23. Competition Analysis
23.1. Competition Benchmarking
12.1.A. Competition Dashboard
23.2. Key Development Analysis
23.3. Competition Deep Dive
23.3.1. Surmodics, Inc.
23.3.1.1. Overview
23.3.1.2. Product Portfolio
23.3.1.3. Key Financials
23.3.1.4. SWOT Analysis
23.3.1.5. Sales Footprint
23.3.1.6. Strategy Overview
23.3.1.6.1. Marketing Strategy
23.3.1.6.2. Product Strategy
23.3.1.6.3. Channel Strategy
23.3.2. MESO SCALE DIAGNOSTICS, LLC.
23.3.2.1. Overview
23.3.2.2. Product Portfolio
23.3.2.3. Key Financials
23.3.2.4. SWOT Analysis
23.3.2.5. Sales Footprint
23.3.2.6. Strategy Overview
23.3.2.6.1. Marketing Strategy
23.3.2.6.2. Product Strategy
23.3.2.6.3. Channel Strategy
23.3.3. Abbott (Core Laboratory)
23.3.3.1. Overview
23.3.3.2. Product Portfolio
23.3.3.3. Key Financials
23.3.3.4. SWOT Analysis
23.3.3.5. Sales Footprint
23.3.3.6. Strategy Overview
23.3.3.6.1. Marketing Strategy
23.3.3.6.2. Product Strategy
23.3.3.6.3. Channel Strategy
23.3.4. Siemens-healthineers (Siemens Medical Solutions USA, Inc)
23.3.4.1. Overview
23.3.4.2. Product Portfolio
23.3.4.3. Key Financials
23.3.4.4. SWOT Analysis
23.3.4.5. Sales Footprint
23.3.4.6. Strategy Overview
23.3.4.6.1. Marketing Strategy
23.3.4.6.2. Product Strategy
23.3.4.6.3. Channel Strategy
23.3.5. PerkinElmer Inc.
23.3.5.1. Overview
23.3.5.2. Product Portfolio
23.3.5.3. Key Financials
23.3.5.4. SWOT Analysis
23.3.5.5. Sales Footprint
23.3.5.6. Strategy Overview
23.3.5.6.1. Marketing Strategy
23.3.5.6.2. Product Strategy
23.3.5.6.3. Channel Strategy
23.3.6. BD Biosciences
23.3.6.1. Overview
23.3.6.2. Product Portfolio
23.3.6.3. Key Financials
23.3.6.4. SWOT Analysis
23.3.6.5. Sales Footprint
23.3.6.6. Strategy Overview
23.3.6.6.1. Marketing Strategy
23.3.6.6.2. Product Strategy
23.3.6.6.3. Channel Strategy
23.3.7. ThermoFisher Scientific Inc.
23.3.7.1. Overview
23.3.7.2. Product Portfolio
23.3.7.3. Key Financials
23.3.7.4. SWOT Analysis
23.3.7.5. Sales Footprint
23.3.7.6. Strategy Overview
23.3.7.6.1. Marketing Strategy
23.3.7.6.2. Product Strategy
23.3.7.6.3. Channel Strategy
23.3.8. Zoetis Inc.
23.3.8.1. Overview
23.3.8.2. Product Portfolio
23.3.8.3. Key Financials
23.3.8.4. SWOT Analysis
23.3.8.5. Sales Footprint
23.3.8.6. Strategy Overview
23.3.8.6.1. Marketing Strategy
23.3.8.6.2. Product Strategy
23.3.8.6.3. Channel Strategy
23.3.9. Promega Corporation
23.3.9.1. Overview
23.3.9.2. Product Portfolio
23.3.9.3. Key Financials
23.3.9.4. SWOT Analysis
23.3.9.5. Sales Footprint
23.3.9.6. Strategy Overview
23.3.9.6.1. Marketing Strategy
23.3.9.6.2. Product Strategy
23.3.9.6.3. Channel Strategy
23.3.10. F. Hoffmann- La Roche Ltd.
23.3.10.1. Overview
23.3.10.2. Product Portfolio
23.3.10.3. Key Financials
23.3.10.4. SWOT Analysis
23.3.10.5. Sales Footprint
23.3.10.6. Strategy Overview
23.3.10.6.1. Marketing Strategy
23.3.10.6.2. Product Strategy
23.3.10.6.3. Channel Strategy
23.3.11. bioMérieux SA
23.3.11.1. Overview
23.3.11.2. Product Portfolio
23.3.11.3. Key Financials
23.3.11.4. SWOT Analysis
23.3.11.5. Sales Footprint
23.3.11.6. Strategy Overview
23.3.11.6.1. Marketing Strategy
23.3.11.6.2. Product Strategy
23.3.11.6.3. Channel Strategy
23.3.12. Elabscience Biotechnology Inc.
23.3.12.1. Overview
23.3.12.2. Product Portfolio
23.3.12.3. Key Financials
23.3.12.4. SWOT Analysis
23.3.12.5. Sales Footprint
23.3.12.6. Strategy Overview
23.3.12.6.1. Marketing Strategy
23.3.12.6.2. Product Strategy
23.3.12.6.3. Channel Strategy
23.3.13. Innovative Research, Inc.
23.3.13.1. Overview
23.3.13.2. Product Portfolio
23.3.13.3. Key Financials
23.3.13.4. SWOT Analysis
23.3.13.5. Sales Footprint
23.3.13.6. Strategy Overview
23.3.13.6.1. Marketing Strategy
23.3.13.6.2. Product Strategy
23.3.13.6.3. Channel Strategy
23.3.14. QIAGEN N.V.
23.3.14.1. Overview
23.3.14.2. Product Portfolio
23.3.14.3. Key Financials
23.3.14.4. SWOT Analysis
23.3.14.5. Sales Footprint
23.3.14.6. Strategy Overview
23.3.14.6.1. Marketing Strategy
23.3.14.6.2. Product Strategy
23.3.14.6.3. Channel Strategy
23.3.15. Merck KgaA
23.3.15.1. Overview
23.3.15.2. Product Portfolio
23.3.15.3. Key Financials
23.3.15.4. SWOT Analysis
23.3.15.5. Sales Footprint
23.3.15.6. Strategy Overview
23.3.15.6.1. Marketing Strategy
23.3.15.6.2. Product Strategy
23.3.15.6.3. Channel Strategy
23.3.16. Bio-Rad Laboratories, Inc.
23.3.16.1. Overview
23.3.16.2. Product Portfolio
23.3.16.3. Key Financials
23.3.16.4. SWOT Analysis
23.3.16.5. Sales Footprint
23.3.16.6. Strategy Overview
23.3.16.6.1. Marketing Strategy
23.3.16.6.2. Product Strategy
23.3.16.6.3. Channel Strategy
23.3.17. Creative Diagnostics
23.3.17.1. Overview
23.3.17.2. Product Portfolio
23.3.17.3. Key Financials
23.3.17.4. SWOT Analysis
23.3.17.5. Sales Footprint
23.3.17.6. Strategy Overview
23.3.17.6.1. Marketing Strategy
23.3.17.6.2. Product Strategy
23.3.17.6.3. Channel Strategy
23.3.18. Cell Signaling Technology, Inc.
23.3.18.1. Overview
23.3.18.2. Product Portfolio
23.3.18.3. Key Financials
23.3.18.4. SWOT Analysis
23.3.18.5. Sales Footprint
23.3.18.6. Strategy Overview
23.3.18.6.1. Marketing Strategy
23.3.18.6.2. Product Strategy
23.3.18.6.3. Channel Strategy
23.3.19. NEW HORIZONS DIAGNOSTIC CORPORATION
23.3.19.1. Overview
23.3.19.2. Product Portfolio
23.3.19.3. Key Financials
23.3.19.4. SWOT Analysis
23.3.19.5. Sales Footprint
23.3.19.6. Strategy Overview
23.3.19.6.1. Marketing Strategy
23.3.19.6.2. Product Strategy
23.3.19.6.3. Channel Strategy
23.3.20. DiaSorin S.p.A.
23.3.20.1. Overview
23.3.20.2. Product Portfolio
23.3.20.3. Key Financials
23.3.20.4. SWOT Analysis
23.3.20.5. Sales Footprint
23.3.20.6. Strategy Overview
23.3.20.6.1. Marketing Strategy
23.3.20.6.2. Product Strategy
23.3.20.6.3. Channel Strategy
23.3.21. H.U. Group Holdings Inc (Fujirebio Holdings, Inc.)
23.3.21.1. Overview
23.3.21.2. Product Portfolio
23.3.21.3. Key Financials
23.3.21.4. SWOT Analysis
23.3.21.5. Sales Footprint
23.3.21.6. Strategy Overview
23.3.21.6.1. Marketing Strategy
23.3.21.6.2. Product Strategy
23.3.21.6.3. Channel Strategy
23.3.22. IDEXX Laboratories Inc.
23.3.22.1. Overview
23.3.22.2. Product Portfolio
23.3.22.3. Key Financials
23.3.22.4. SWOT Analysis
23.3.22.5. Sales Footprint
23.3.22.6. Strategy Overview
23.3.22.6.1. Marketing Strategy
23.3.22.6.2. Product Strategy
23.3.22.6.3. Channel Strategy
23.3.23. Randox Laboratories Ltd.
23.3.23.1. Overview
23.3.23.2. Product Portfolio
23.3.23.3. Key Financials
23.3.23.4. SWOT Analysis
23.3.23.5. Sales Footprint
23.3.23.6. Strategy Overview
23.3.23.6.1. Marketing Strategy
23.3.23.6.2. Product Strategy
23.3.23.6.3. Channel Strategy
23.3.24. Biopanda Reagents Ltd.
23.3.24.1. Overview
23.3.24.2. Product Portfolio
23.3.24.3. Key Financials
23.3.24.4. SWOT Analysis
23.3.24.5. Sales Footprint
23.3.24.6. Strategy Overview
23.3.24.6.1. Marketing Strategy
23.3.24.6.2. Product Strategy
23.3.24.6.3. Channel Strategy
23.3.25. Shenzhen Bioeasy Biotechnology Co.,Ltd.
23.3.25.1. Overview
23.3.25.2. Product Portfolio
23.3.25.3. Key Financials
23.3.25.4. SWOT Analysis
23.3.25.5. Sales Footprint
23.3.25.6. Strategy Overview
23.3.25.6.1. Marketing Strategy
23.3.25.6.2. Product Strategy
23.3.25.6.3. Channel Strategy
23.3.26. Quidel Corporation
23.3.26.1. Overview
23.3.26.2. Product Portfolio
23.3.26.3. Key Financials
23.3.26.4. SWOT Analysis
23.3.26.5. Sales Footprint
23.3.26.6. Strategy Overview
23.3.26.6.1. Marketing Strategy
23.3.26.6.2. Product Strategy
23.3.26.6.3. Channel Strategy
23.3.27. Advnt Biotechnologies
23.3.27.1. Overview
23.3.27.2. Product Portfolio
23.3.27.3. Key Financials
23.3.27.4. SWOT Analysis
23.3.27.5. Sales Footprint
23.3.27.6. Strategy Overview
23.3.27.6.1. Marketing Strategy
23.3.27.6.2. Product Strategy
23.3.27.6.3. Channel Strategy
23.3.28. RESPONSE BIOMEDICAL
23.3.28.1. Overview
23.3.28.2. Product Portfolio
23.3.28.3. Key Financials
23.3.28.4. SWOT Analysis
23.3.28.5. Sales Footprint
23.3.28.6. Strategy Overview
23.3.28.6.1. Marketing Strategy
23.3.28.6.2. Product Strategy
23.3.28.6.3. Channel Strategy
23.3.29. Danaher
23.3.29.1. Overview
23.3.29.2. Product Portfolio
23.3.29.3. Key Financials
23.3.29.4. SWOT Analysis
23.3.29.5. Sales Footprint
23.3.29.6. Strategy Overview
23.3.29.6.1. Marketing Strategy
23.3.29.6.2. Product Strategy
23.3.29.6.3. Channel Strategy
24. Assumptions and Acronyms Used
25. Research Methodology
Explore Healthcare Insights
View Reports
Coronavirus Immunoassay Market
